Regulatorische Updates
24. Sept. 2026•1 Min. Lesezeit
MFDS reviews K‑NASS system to strengthen monitoring of medical narcotics misuse
The Korean Ministry of Food and Drug Safety inspected the pilot K‑NASS system, aiming to detect misuse and illegal distribution of medical narcotics more rapidly.
1
Regulatorische Updates
24. Sept. 2026•1 Min. Lesezeit
MFDS Reaffirms Strict Evidence Standards for Health Functional Food Ingredients
MFDS says statistical significance alone isn’t enough for functional food ingredient approval; proper trial design and consistent functional outcomes are required.
Regulatorische Updates
23. Sept. 2026•1 Min. Lesezeit
Korean Health & Welfare Committee Tensions Over MFDS Role Amid Minister Nominee Scrutiny
The first regular Health and Welfare Committee meeting showed sharp partisan clashes, focusing on the MFDS’s responsibility linked to the Justice Minister nominee.
Regulatorische Updates
22. Sept. 2026•1 Min. Lesezeit
MFDS Revises Standard Decoction Definition, Holds Briefing for Herbal Medicine Manufacturers
The Korean MFDS announced a meeting on Oct 10 to guide herbal medicine makers on the new standard decoction definition effective Sep 2024 and share change‑approval procedures.
Regulatorische Updates
22. Sept. 2026•1 Min. Lesezeit
MFDS Revises Digital Therapeutic Device Clinical Trial Guidelines for 7 Indications
South Korea's MFDS has detailed new review criteria and updated guidelines for digital therapeutic device trials covering seven mental‑health and substance‑use disorders.
Regulatorische Updates
21. Sept. 2026•1 Min. Lesezeit
MFDS recalls 4 hand sanitizers after content non‑compliance in nationwide test
The Korean Food & Drug Administration tested 100 top‑selling hand sanitizers and found four failing the ingredient‑content standards, prompting sales suspension, recall and disposal.
Regulatorische Updates
21. Sept. 2026•1 Min. Lesezeit
MFDS Survey Flags Issues at Five Korean Clinical Trial Sites
MFDS’ recent survey identified corrective findings at five hospitals, while Korea University Medical Center had no issues.
Regulatorische Updates
20. Sept. 2026•1 Min. Lesezeit
MFDS to Classify GLP-1 Obesity Drugs as Potentially Abusable by September
South Korea's MFDS plans to finish designating GLP‑1 obesity treatments such as Wegovy and Mounjaro as ‘drugs with potential for abuse’ by September, requiring prescription‑only sales and mandatory labeling.
Regulatorische Updates
18. Sept. 2026•1 Min. Lesezeit
World’s First Global Cosmetics Regulatory Agency Platform Launched in Seoul
The Global Cosmetics Regulatory Agency Council (GCORAS) was officially inaugurated in Seoul, led by South Korea’s Ministry of Food and Drug Safety, with meetings running through Sept 9.
Regulatorische Updates
18. Sept. 2026•1 Min. Lesezeit
MFDS to Add Stevens-Johnson Syndrome to Labels of 56 Oral Aripiprazole Products
South Korea’s MFDS will amend the approval conditions for 56 oral aripiprazole medicines, adding Stevens-Johnson syndrome as a reported adverse reaction. The change involves 12 manufacturers.
Regulatorische Updates
17. Sept. 2026•1 Min. Lesezeit
MFDS reports 7 GMP observations for Kyungbang Shinyak, all classified as "Other"
The Ministry of Food and Drug Safety disclosed that Kyungbang Shinyak received seven GMP observations in facility equipment and manufacturing, all categorized as "Other" with no major issues.
Regulatorische Updates
16. Sept. 2026•1 Min. Lesezeit
Korea to Merge Three Drug Safety Agencies into New Korean Pharmaceutical Safety Agency
The government plans to consolidate the Korean Rare Essential Medicines Center, the Pharmaceutical Safety Management Agency and the Vaccine Safety Technology Support Center under a new Korean Pharmaceutical Safety Agency.